Select Page

Scientific Advisory Board Recommendation

“The observation of symptom remission in ADRC-treated patients, illustrated in Emilie’s case, underscores the potential of these cells to profoundly influence physiology in ways that remain mechanistically unclear. As a scientist with extensive experience in epigenetic reprogramming of stem cells, I believe this phenomenon presents a critical opportunity for systematic investigation.

By unraveling the molecular mechanisms underlying ADRC-driven reprogramming, we could identify biomarkers or genetic conditions that predict treatment success. This understanding could not only enable targeted patient selection for ADRC therapy but also pave the way for broader, innovative applications of this promising cell therapy.”

Mary {Cindy) Farach Carson, Ph.D.
Professor Rice University
AMBROSE SCIENTIFIC ADVISORY BOARD

“Ambrose Cell Therapy’s approach for treating patients with rare genetic disorders like Emilie’s shows surprising results. The hypothesis that ADRCs could modulate gene expression via epigenetic regulation should be evaluated in rigorous clinical trials.”

Gianni Soldati Ph.D.
FOUNDER AND PRESIDENT OF THE
SWISS STEM CELL FOUNDATION, CHIEF SCIENCE OFFICER
AMBROSE CHIEF SCIENTIFIC OFFICER

“The remarkable therapeutic effect of autologous ADRC transplantation for diverse rare genetic diseases such as Emilie suggests that – in addition to wound healing and immunomodulatory mechanisms -ADRCs modify pathogenic gene expression in certain patients.
An FDA-approved clinical trial that includes advanced cell sample testing before and after ADRC infusion to test the hypothesis that ADRCs induce epigenetic modifications that are responsible -at least in part-for clinical improvement in rare disease patients is called for.”

Bruno Peault Ph.D.
PH.D. PROFESSOR UCLA
AMBROSE SCIENTIFIC ADVISORY BOARD MEMBER

11 + 10 =